Tirzepatide is a novel once-weekly subcutaneous injection-based hypoglycemic drug. It functions through a unique dual-agonist mechanism, targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual-action mechanism enables it to effectively improve the glycemic control of patients with type 2 diabetes, with its effects being significantly superior to many traditional hypoglycemic drugs and some single receptor agonists. Besides its potent hypoglycemic efficacy, Tirzepatide demonstrates outstanding weight loss effects in clinical studies, with an average weight reduction of over 20%. This makes it a breakthrough choice in the field of obesity management. Moreover, it can bring cardiovascular and metabolic benefits, such as lowering blood pressure and cholesterol levels. Although common side effects include gastrointestinal reactions (such as nausea, vomiting, and diarrhea), most of these symptoms tend to diminish as the treatment continues. As the first dual agonist of GIP/GLP-1 receptors, Tirzepatide not only represents an important advancement in diabetes treatment but also opens up a new direction for the management of metabolic diseases. Currently, it is being further studied for use in treating obesity and related complications in non-diabetic patients.
 |
 |
 |
 |
 |
 |
Core Benefits
Powerful Glycemic Control: Dual Mechanism Stabilizes Blood Glucose Curves
Tirzepatide activates both GLP-1 and GIP receptors simultaneously, creating a synergistic effect where "1+1>2." GLP-1 receptor activation promotes glucose-dependent insulin secretion, inhibits glucagon release, and delays gastric emptying. GIP receptor activation further enhances insulin response and improves insulin sensitivity. The SURPASS clinical trial series demonstrated that Tirzepatide reduced HbA1c by an average of 1.5%-2.6% in patients with type 2 diabetes. The highest dose group (15mg) achieved HbA1c levels below 7% (the American Diabetes Association target) in 92% of patients, significantly outperforming single GLP-1 receptor agonists (e.g., semaglutide). Its glucose control effect is dose-dependent, with a lower risk of hypoglycemia, making it particularly suitable for patients with significant blood glucose fluctuations.
Significant Weight Loss: Multi-Target Intervention in Energy Metabolism
Tirzepatide suppresses appetite and promotes lipolysis through dual pathways:
Central Regulation: Activates the hypothalamic satiety center to reduce food intake.
Peripheral Action: Delays gastric emptying to prolong satiety duration
Metabolic Optimization: Increases glucose uptake in adipose tissue, promoting fat breakdown for energy.
In the SURMOUNT-1 trial, obese or overweight patients (BMI ≥ 27 kg/m² with complications) achieved an average weight loss of 15%–22.5% after 72 weeks of tirzepatide treatment. Among them, 63% lost over 20% of their body weight, with efficacy approaching that of bariatric surgery. Its mechanism advantage lies in simultaneously reducing fat mass while minimizing lean body mass loss, avoiding the muscle wasting associated with traditional weight-loss medications.
Improving Dyslipidemia: Reducing Cardiovascular Risk
Tirzepatide significantly modulates lipid metabolism, lowering atherosclerosis risk:
Reduces triglycerides (TG): The highest dose group achieved a 24.8% decrease in TG levels.
Optimizing cholesterol profile: LDL-C decreased by 8%, HDL-C increased by 11%
Reducing very low-density lipoprotein (VLDL): VLDL-C decreased by 23.7%, inhibiting hepatic lipid synthesis.
These changes reduce the risk of cardiovascular events such as non-fatal stroke and myocardial infarction, providing additional protection for patients with type 2 diabetes.
Potential Multi-Organ Protection: Expanding Clinical Application Prospects
Ongoing research suggests Tirzepatide may offer therapeutic benefits for the following conditions:
Non-Alcoholic Steatohepatitis (NASH): By reducing hepatic fat accumulation and slowing fibrosis progression
Obstructive Sleep Apnea: By improving upper airway collapse through weight reduction
Heart Failure: Potentially alleviating cardiac workload by optimizing metabolism.
Safety and Convenience of Administration
Tirzepatide is administered as a once-weekly subcutaneous injection, offering superior compliance compared to traditional daily medications. Common side effects include mild gastrointestinal reactions (such as nausea and diarrhea), which are typically transient and diminish with dose adjustment. Contraindications include a history of medullary thyroid carcinoma, pregnancy, and lactation. Currently, tirzepatide is FDA-approved for type 2 diabetes (brand name Mounjaro®) and obesity (brand name Zepbound®), with additional global studies exploring further indications.
Summary
Leveraging its unique dual receptor agonist mechanism, Tirzepatide demonstrates comprehensive advantages in glycemic control, weight reduction, lipid regulation, and potential organ protection. It offers a revolutionary tool for treating metabolic disorders, particularly benefiting type 2 diabetes patients requiring simultaneous management of blood glucose and body weight.
Clinical application
Type 2 Diabetes Treatment: Breakthrough Glycemic Control
Tirzepatide is the world's first approved dual GIP/GLP-1 receptor agonist. By activating two intestinal hormone receptors, it significantly improves glycemic control while reducing hypoglycemia risk. Its core clinical advantages include:
Potent Glycemic Reduction
In the SURPASS Phase III trials, monotherapy with Tirzepatide achieved an average HbA1c reduction of 1.5%–2.6%. The highest dose group (15mg) brought 51.7% of patients to normal blood glucose levels (HbA1c <5.7%), outperforming single GLP-1 receptor agonists (e.g., semaglutide).
In combination therapy, compared to basal insulin (e.g., insulin degludec), tirzepatide further reduced HbA1c by 0.95%-2.49% without increasing hypoglycemia risk.
Multiple Metabolic Improvements
Weight Loss: Patients achieved an average weight reduction of 5.0kg–9.5kg (5mg–15mg dose groups), with the highest dose group achieving an 11% weight loss rate, significantly outperforming traditional antidiabetic drugs.
Lipid Regulation: Reduced triglycerides (TG) by 24.8% and optimized cholesterol profile (LDL-C decreased by 8%, HDL-C increased by 11%).
Cardiovascular Protection: May reduce cardiovascular event risk by improving lipids and lowering blood pressure (currently being validated in the ongoing SURPASS-CVOT trial).
Dosage Convenience
Once-weekly subcutaneous injection offers superior compliance compared to daily GLP-1 receptor agonists.
Obesity Treatment: Revolutionary Weight Loss Effects
Tirzepatide is the first approved dual GIP/GLP-1 agonist for obesity treatment, demonstrating significantly greater weight loss than existing drugs:
Core Trial Data
SURMOUNT-1: Obese patients (BMI ≥30 kg/m²) achieved an average weight loss of 22.5% (approximately 24 kg) after 72 weeks of tirzepatide treatment, with 63% losing over 20% of body weight-results comparable to bariatric surgery.
SURMOUNT-2: Among overweight/obese patients with type 2 diabetes, average weight loss ranged from 15% to 21% (dose-dependent), significantly exceeding the 3% reduction in the placebo group.
Mechanism Advantages
Dual Action: GIP receptor activation further reduces appetite and increases energy expenditure, synergizing with GLP-1 receptor activation to overcome the efficacy limitations of single-target therapies.
Muscle Preservation: Weight loss occurs with reduced fat infiltration and decreased skeletal muscle fat content, preventing muscle loss associated with traditional weight-loss drugs.
Efficacy in Special Populations
Genetic Obesity: In patients with genetic obesity due to melanocortin-4 receptor (MC4R) deficiency, tirzepatide achieved weight loss comparable to non-genetic obesity (18.3% weight loss at 72 weeks).
Metabolic-Associated Steatohepatitis (MASLD): Significantly reduces hepatic fat content by 63% and improves liver fibrosis markers.
Other Potential Indications: Expanding Therapeutic Frontiers
SURMOUNT-OSA Trial: Tirzepatide reduced the apnea-hypopnea index (AHI) by 27.4-30.4 events/hour in patients with moderate-to-severe OSA. Over 40% of patients achieved normalized or significantly improved AHI, while cardiovascular risk markers (e.g., high-sensitivity C-reactive protein) were also lowered.
The ongoing SURPASS-CVOT trial will evaluate its potential to reduce cardiovascular event risk in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
Early studies suggest Tirzepatide may slow estimated glomerular filtration rate (eGFR) decline and improve liver inflammation and fibrosis. Related Phase III trials are underway.
Summary of Clinical Advantages
Dual Mechanism: Synergistic activation of GIP/GLP-1 receptors achieves a "1+1>2" metabolic regulatory effect.
Comprehensive Benefits: Simultaneously controls blood glucose, promotes weight loss, regulates lipids, and provides cardiovascular protection, simplifying treatment regimens for obese patients with type 2 diabetes.
Long-Term Safety: Clinical trials showed no increased risk of severe hypoglycemia or cardiovascular events. Gastrointestinal side effects (e.g., nausea, diarrhea) were predominantly mild to moderate and transient.
Future Outlook: Tirzepatide is approved for type 2 diabetes and obesity, with ongoing exploration in cardiovascular disease, chronic kidney disease, and NASH. As research advances, it holds promise to become a cornerstone drug in metabolic disease management, reshaping the clinical treatment landscape.